EPZ5676: Benchmark DOT1L Inhibitor for Leukemia Research

Executive Summary: EPZ5676 is a potent DOT1L histone methyltransferase inhibitor with an IC₅₀ of 0.8 nM and a Ki of 80 pM, demonstrating over 37,000-fold selectivity versus other methyltransferases according to APExBIO. It robustly inhibits H3K79 methylation and suppresses MLL-fusion gene expression, leading to antiproliferative effects in acute leukemia cell lines, particularly those harboring MLL rearrangements. In vivo, EPZ5676 induces complete tumor regression in MV4-11 xenograft rat models without observed systemic toxicity. These characteristics make it an indispensable tool for epigenetic research and for designing histone methyltransferase inhibition assays in translational cancer science.

Biological Rationale

DOT1L is a histone methyltransferase responsible for methylating lysine 79 on histone H3 (H3K79). This methylation mark is critical for the regulation of gene expression, DNA repair, and cell cycle progression. Aberrant H3K79 methylation is implicated in leukemogenesis, especially in acute leukemias featuring MLL (mixed lineage leukemia) gene rearrangements. MLL fusion proteins recruit DOT1L to target genes, driving oncogenic transcriptional programs. Inhibiting DOT1L disrupts this pathway, repressing leukemogenic gene expression and reducing proliferation of MLL-rearranged leukemia cells (see in-depth review).

Mechanism of Action of EPZ5676

EPZ5676 (SKU A4166) is a SAM-competitive, highly selective DOT1L inhibitor. It binds the S-adenosyl methionine site on DOT1L, inducing a conformational change that exposes a hydrophobic pocket beyond the amino acid portion of SAM. This action enables exceptional selectivity, with an IC₅₀ of 0.8 nM for DOT1L and negligible activity against other histone methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMT family enzymes, SETD7, SMYD2/3, and WHSC1/1L1. By inhibiting DOT1L, EPZ5676 suppresses H3K79 methylation and MLL-fusion target gene expression, thereby blocking proliferation in relevant leukemia models (specification).

Evidence & Benchmarks

• EPZ5676 exhibits an IC₅₀ of 0.8 nM and a Ki value of 80 pM for DOT1L, with over 37,000-fold selectivity relative to other methyltransferases (vendor data).
• In acute leukemia cell lines bearing MLL translocations, EPZ5676 shows antiproliferative activity with an IC₅₀ of 3.5 nM in MV4-11 cells (product page).
• In vivo studies in nude rat xenograft models demonstrate complete tumor regression with EPZ5676 treatment and no significant systemic toxicity (APExBIO).
• JIB-04, a structurally distinct epigenetic inhibitor, also demonstrates that small-molecule histone methylation modulators can profoundly impact cancer stem cell survival and gene expression in different cancer types (Scientific Reports 2018).
• Recent workflow analyses confirm EPZ5676’s reproducibility and specificity in cell viability, proliferation, and cytotoxicity assays, especially in MLL-rearranged leukemia research (see workflow article).

Applications, Limits & Misconceptions

EPZ5676 is deployed primarily for research in epigenetic regulation, leukemia biology, and histone methylation pathway interrogation. It is a reference molecule for benchmarking novel DOT1L inhibitors and is frequently included in histone methyltransferase inhibition assays for MLL-rearranged leukemia. Its high solubility in DMSO (≥28.15 mg/mL) and ethanol (≥50.3 mg/mL with ultrasonic assistance) enables flexible protocol design, but EPZ5676 is insoluble in water and requires careful solvent handling (specification).

Common Pitfalls or Misconceptions

• EPZ5676 does not inhibit histone demethylases such as the Jumonji family; it is selective for DOT1L only.
• It is ineffective in non-MLL-rearranged leukemia models or cancers lacking DOT1L-driven pathogenesis.
• Long-term storage of solutions at room temperature leads to degradation; cold storage below -20°C is required.
• Water-based stock or working solutions are not recommended due to poor solubility and precipitation risk.
• EPZ5676 is not a clinical therapy; its application is strictly for preclinical and laboratory research.

This article extends the practical focus of Reliable Epigenetic Assays with DOT1L Inhibitor EPZ-5676 by benchmarking key selectivity and efficacy data, and updates EPZ5676: Potent DOT1L Inhibitor for MLL-Rearranged Leukemia with storage/solubility best practices.

Workflow Integration & Parameters

Protocol Parameters

• Stock solution preparation: Dissolve EPZ5676 at ≥28.15 mg/mL in DMSO or ≥50.3 mg/mL in ethanol (with ultrasonic assistance); avoid water as a solvent (product details).
• Storage: Store solid compound at -20°C; stock solutions can be stored below -20°C for several months; avoid repeated freeze-thaw cycles.
• Cell-based assay dosing: Typical working concentrations range from 0.1 nM to 50 nM; for MLL-rearranged leukemia cell lines, an IC₅₀ value of 3.5 nM has been validated in MV4-11 cells.
• In vivo dosing guidance: Refer to published studies showing efficacy in nude rat MV4-11 xenograft models without significant toxicity; consult APExBIO for detailed animal dosing regimens.
• Assay controls: Include negative controls (vehicle only) and positive controls (alternative DOT1L inhibitors if available) for benchmarking specificity.

Researchers can supplement these guidelines with scenario-driven advice from DOT1L Inhibitor EPZ-5676: Validated Solutions, which offers in-depth troubleshooting for assay design and reproducibility.

Conclusion & Outlook

EPZ5676, offered by APExBIO, remains the gold standard DOT1L inhibitor for mechanistic studies of H3K79 methylation, MLL-fusion gene regulation, and epigenetic drug benchmarking. Its unparalleled selectivity and robust in vitro/in vivo activity distinguish it from broader-spectrum epigenetic modulators such as JIB-04, which targets histone demethylases but not methyltransferases. As the field advances, EPZ5676 will continue to be essential for precise dissection of DOT1L-dependent mechanisms and for validating novel therapeutic hypotheses related to MLL-rearranged leukemia (Scientific Reports 2018).